Japan performs world’s first heart muscle stem‑cell surgery using iPS sheets
A team at Osaka Keisatsu Hospital in Japan transplanted sheets of heart muscle cells made from induced pluripotent stem (iPS) cells into the heart of a woman in her 50s during a hour‑long surgery on Tuesday, September 29, 2026. This marks the first clinical use of the regenerative therapy after it received conditional government approval in March 2026. The procedure, developed by surgeon Yoshiki Sawa and Nobel laureate Shinya Yamanaka, aims to treat patients with ischemic heart disease who have exhausted other options. In earlier trials on eight similar patients, all reported eased symptoms and four showed improved heart function. Sawa said the goal is to boost the patient’s quality of life, with plans to treat 75 more people by 2033 and seek full authorization after proving safety and efficacy over the next seven years. Japan also gave conditional approval in March for a Parkinson’s disease treatment that transplants iPS cells into the brain.
For Nigerians, heart disease remains a leading cause of death, and this breakthrough highlights where global regenerative medicine is heading. While the therapy is not yet available locally, it signals future possibilities for treating heart failure and underscores the value of investing in medical research and clinical trials at home. As such advances emerge, staying informed about their potential availability and considering preventive lifestyle changes—like regular check‑ups, balanced diet, and exercise—can help mitigate risk.
With heart failure affecting many families, would you support increased funding for stem‑cell research in Nigeria, or would you prefer to focus on accessible preventive measures today?